What You Ought to Know:
– Catalio Capital Management, LP (“Catalio”), a healthcare funding agency, at present introduced the profitable shut of its fourth enterprise fund, Catalio Nexus Fund IV (“Fund IV”), with over $400M in commitments throughout the Fund and its associated co-investment autos.
– Launched in 2020 by Co-Founders George Petrocheilos and Dr. Jacob Vogelstein, Catalio at the moment manages $2B in property throughout its non-public fairness, non-public credit score, and public equities methods.
A Differentiated Funding Strategy in Healthcare
Catalio’s core funding method facilities on figuring out and supporting transformative healthcare corporations which might be spun out of main educational establishments and led by repeat founders with deep scientific experience. Their Nexus funds have invested in over 80 non-public corporations because the agency’s inception 5 years in the past. Catalio has additionally efficiently bought or taken public a variety of companies through the years, persistently making distributions to its restricted companions yearly since its founding.
Fund IV’s Early Investments and Strategic Focus
Up to now, Fund IV has already made 16 investments, showcasing Catalio’s dedication to partnering with world-class groups and constructing category-defining life sciences companies throughout all levels, from inception to IPO and past.
Current highlights in Fund IV’s funding portfolio embody:
- Most cancers Diagnostics: Co-leading PinkDx’s $40 million Sequence A fundraise, centered on growing diagnostics for gynecological cancers.
- AI-Enabled Drug Discovery: Investing within the Sequence A financing of Superluminal Medicines, increasing Catalio’s portfolio in AI-enabled drug discovery.
- New Firm Launches (Immunology & Irritation): Launching Rhapsogen, co-founded by Catalio Enterprise Associate Dr. Jeffrey Ravetch at Rockefeller College, and TBD Pharma, co-founded by Catalio Enterprise Associate Dr. Bert Vogelstein at Johns Hopkins College.
- Late-Stage Investments: Taking part in Crucial Care’s $150M Sequence E financing (a medical gadget firm), a PIPE for Protara Therapeutics (an oncology firm), and Alentis Therapeutics’ $180M Sequence D financing (an organization growing antibody drug conjugates for oncology indications).
“We’re grateful for the continued confidence and robust help we acquired for Fund IV from each new and current excessive caliber buyers,” stated Olga Maltseva, Associate & Head of Operations at Catalio. “These new funds will enable Catalio to proceed benefiting from alternatives in a historic purchaser’s market in biotech, and to maintain distinguishing ourselves as a number one revolutionary healthcare investor across the globe.”
